Valent Pharmaceuticals

Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals, is a global diversified pharmaceutical company that develops, manufactures, and markets a broad range of products primarily in gastroenterology, dermatology, and eye health. The company operates through several key segments, including Salix Pharmaceuticals, Ortho Dermatologics, and its majority-owned subsidiary Bausch + Lomb. Following a significant corporate restructuring and name change in 2018, the company has focused on reducing debt and driving organic growth through its core product portfolio. Key commercial assets include Xifaxan for irritable bowel syndrome and Vyzulta for glaucoma. Headquartered in Laval, Canada, Bausch Health maintains a significant global footprint with products available in approximately 100 countries.